EMA Authorised: Gazyvaro (obinutuzumab) — Roche Registration GmbH

View source ↗

Summary

EMA authorised Gazyvaro (obinutuzumab) by Roche Registration GmbH for chronic lymphocytic leukemia (a B-cell leukemia).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Gazyvaro (obinutuzumab)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Lymphocytic, Chronic, B-Cell. MAH: Roche Registration GmbH. Decision date: 05/03/2026